Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
eGenesis develops gene-edited pig organs for transplant into patients with organ failure.
eGenesis is a biotech company trying to solve one of medicine's worst shortages: there are far more people who need a new organ than there are human organs to go around. Its answer is to raise pigs whose organs have been edited at the genetic level so they can be transplanted into people without being immediately rejected or passing along pig viruses. The company calls this "xenotransplantation" β transplanting organs across species.
The science is a genetic cleanup job. A pig heart or kidney is roughly the right size and shape for a human, but a pig's cells carry sugar molecules that a human immune system attacks on sight, plus pig DNA contains dormant viruses that could wake up inside a patient. eGenesis uses gene editing to strip out the problematic pig genes, knock out the viruses, and add a handful of human genes to help the organ blend in. The company thinks of it as making the pig organ look human enough to be accepted. That work is aimed at patients with organ failure β people on transplant waiting lists, many of whom die before a human organ arrives. In early 2025, eGenesis reported that a gene-edited pig kidney it produced kept a living patient alive and making urine for a meaningful stretch of time, a first-of-its-kind result. Regulators have been watching closely; the field sits under tight FDA oversight because the risks β immune rejection and cross-species infection β are serious.
eGenesis is not yet a business that sells much of anything. It is a research-stage company funded by venture investors and partners who are betting that edited pig organs can become a real, repeatable supply of transplantable organs. Its challenges are the usual ones for frontier biotech: proving the organs are safe and durable in people, scaling up a herd of carefully edited pigs, and getting regulators comfortable. If it works, it turns organ donation from a scarce gift into something closer to a manufactured supply.
Saved answer Β· last researched 16 Nov 2026